Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breath Test Indicates Biomarker for Early-Stage Liver Disease

By LabMedica International staff writers
Posted on 24 Aug 2015
Patients with liver disease do not often present with symptoms until the disease is advanced and even then diagnosis is difficult and the symptoms and signs are often general and can be mistaken for other pathologies.

The detection of early-stage liver disease, which is essential to reduce disease progression, and analysis of volatiles in the breath has the potential to deliver this, but only if chemical compounds can be found that are unambiguously associated with a diseased liver.

Scientists at the University of Birmingham (Edgbaston, UK) recruited patients from either the transplant assessment clinic or in wards after being admitted with hepatic encephalopathy from the University Hospital. More...
There were 31 patients suffering from liver disease participated in the pre-transplant measurements. The female to male ratio was 8:23, with a mean age of 55 years. There were a number of etiologies and 11 patients had more than one condition. Breath samples from the group of 31 patients suffering from cirrhosis were first compared with a healthy control group. Then pre-transplant samples of the liver disease sufferers were compared with a sub-cohort of 11 patients who went on to have a liver transplant.

Capnography controlled sampling was used to collect only the alveolar phase of the breath. Patients were asked to breathe normally into a gas tight respiratory system (Intersurgical Limited; Wokingham, UK) containing an in-line carbon dioxide (CO2) mainstream sensor connected to a fast-time response capnometer ,the Capnogard 1265 (Novametrix Medical Systems Inc.; Wallingford, CT, USA). Samples were analyzed on a proton transfer reaction mass spectrometer (PTR-MS, IONICON Analytik GmbH; Innsbruck, Austria).

Seven volatiles were elevated in the breath of patients versus controls. Of these, five showed statistically significant decrease post-transplant: limonene, methanol, 2-pentanone, 2-butanone, and carbon disulfide. On an individual basis limonene has the best diagnostic capability with the area under a receiver operating characteristic curve (AUROC) at 0.91, but this is improved by combining methanol, 2-pentanone and limonene with the AUROC curve equal to 0.95. When the team tested the same patients who had received a new liver, the tests showed that the limonene levels gradually dropped over several days. The scientists deduced that the unmetabolized limonene had been stored in the body fat of people suffering with cirrhosis.

Margaret E. O'Hara, PhD, a coauthor of the study said, “We already knew that people with liver disease have a very distinct smell on the breath and we wanted to find out what caused that smell. Now that we have found a biomarker for the disease in limonene, we can continue to verify how good it is for diagnosing liver disease. In the future we can envisage a small portable breath analyzer that can be used by health professionals to screen for early stage liver disease, leading to earlier treatment and better survival rates.” The study was published online on July 27, 2015, in the journal EbioMedicine.

Related Links:

University of Birmingham
Intersurgical Limited
Novametrix Medical Systems Inc. (Respironics)



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.